研究 | 治疗 | HR+/HER2 + DFS | HR-/HER2 + DFS | 参考文献 |
HERA | 1. 1 year of trastuzumab 2.2 year of trastuzumab | 1.1.73% 2.2. 71% | 1.1. 68% 2.2. 68% | [22] |
ALTTO | trastuzumab and/or lapatinib | 83.87% | 82.17% | |
ExteNET | neratinib | 92.80% | 90.56% | [34] |